Can Fite Biopharma Ltd (NYSEMKT:CANF)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued on Tuesday.
Separately, ValuEngine downgraded shares of Can Fite Biopharma from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 7th.
Can Fite Biopharma (CANF) traded up 2.1026% during midday trading on Tuesday, reaching $1.5928. The company’s stock had a trading volume of 8,790 shares. The firm’s market cap is $27.66 million. Can Fite Biopharma has a 52-week low of $1.50 and a 52-week high of $2.67. The firm has a 50 day moving average of $1.68 and a 200 day moving average of $1.75.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
What are top analysts saying about Can Fite Biopharma Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Can Fite Biopharma Ltd and related companies.